Thus, there was no additional first‐ or second‐line TKI treatment for u‐HCC developed until the introductions of REG3, 4 and LEN.6 Recently, REG was developed as a second‐line option for SOR in patients who met the RESORCE trial criteria,3 after which LEN became available as a first‐line oral TKI targeting VEGF receptors 1‐4, PDGF receptor α, RET, and KIT.6 This evidence concerns the gene KIT and hepatocellular carcinoma.